December 17, 2019
Astellas Pharma launched a tender offer for Nasdaq-listed Audentes Therapeutics, a gene therapy developer based in San Francisco, on December 16 in a deal expected to be worth US$3 billion announced early this month. The Japanese major plans to snap...read more